Arbutus to Participate in Two Upcoming Investor Conferences
07 sept. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
03 août 2023 07h30 HE
|
Arbutus Biopharma Corporation
Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in...
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
20 juil. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
12 juil. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Appoints Two New Executives
10 juil. 2023 16h01 HE
|
Arbutus Biopharma Corporation
Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus...
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
21 juin 2023 07h30 HE
|
Arbutus Biopharma Corporation
Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
21 juin 2023 02h01 HE
|
Arbutus Biopharma Corporation
Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or...
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
07 juin 2023 02h01 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus to Present at Jefferies Healthcare Conference
31 mai 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus to Present at JMP Securities Life Sciences Conference
09 mai 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...